Indian stocks: Visit www.stage2stocks.com →

ANI Pharmaceuticals, Inc.

Stage 4 · Declining · week 8

As of Oct 22, 2026, ANI Pharmaceuticals is in Stage 4, the downtrend phase, now in week 8 (since Aug 27, 2026). It closed at $73.75, 22.3% below its 52-week high and below its 200-day average, which is falling.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. More about the company

$73.75
+2.09% today
$1.7B · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ANIP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S3 13w
S2 16w
S3 15w
S4 21w
S2 15w
S3 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 12w → S3 13w → S2 16w → S3 15w → S4 21w → S1 6w → S2 10w → S3 9w → S2 15w → S3 15w → S4 9w → S1 13w → S4 1w → S3 2w → S4 8w current
Total tracked: 166 weeks across 15 stage runs.

ANIP among Drug Manufacturers - Specialty & Generic43rd of 84 by relative strength

All 84 →
Stocks in Drug Manufacturers - Specialty & Generic ranked by relative strength, with stage and one-month change
#StockStageRS1M
1CPIXStage 2 · wk 2398+6.8%
2ETONStage 2 · wk 3097−10.1%
3ANIKStage 2 · wk 1596+3.5%
4IRWDStage 3 · wk 396−16.4%
5TEVAStage 2 · wk 995+3.1%
6AMRXStage 2 · wk 1995+5.9%
7KNSAStage 2 · wk 7395+6.2%
8AMLXStage 2 · wk 1593−6.6%
…43ANIPStage 4 · wk 838−0.9%
vs 52W High
-22.3%
$70.16 lo$94.90 hi
22.3% below 52W high, ongoing decline
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 8
1w13w26w
Week 8, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-5.4%
200 DMA: $77.93 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
1.20x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-0.9%
3M
-5.0%
6M
-5.5%
YTD
-6.0%
1Y
-22.7%
Scan Membership
Breakout Watch
Latest: 2025-03-25
8 appearances in last 60 days. First seen: 2019-03-19.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 8 · Vol 1.20x
2026-10-21S4
Wk 8 · Vol 0.75x
2026-10-20S4
Wk 8 · Vol 0.68x
2026-10-19S4
Wk 8 · Vol 0.63x
2026-10-16S4
Wk 8 · Vol 0.81x
2026-10-15S4
Wk 7 · Vol 0.59x
2026-10-14S4
Wk 7 · Vol 0.66x
2026-10-13S4
Wk 7 · Vol 0.81x
2026-10-12S4
Wk 7 · Vol 0.78x
2026-10-09S4
Wk 7 · Vol 1.34x
2026-10-08S4
Wk 6 · Vol 1.05x
2026-10-07S4
Wk 6 · Vol 1.11x
Moving averages & range
50 DMA
$73.48
200 DMA
$77.93
52W High
$94.90
52W Low
$70.16
5D Low
$72.24
Resistance levels (recent highs)
20d High
$74.83
60d High
$82.63
120d High
$86.03
250d High
$94.48
Next resistance
+1.5%
to 20d High
P/E (TTM)
16.0
Forward 7.3
Earnings Growth (YoY)
+191.1%
Revenue +25.9%
ROE
+20.5%
Profit margin +11.1%
Dividend Yield
0.00%
P/B 2.6

ANI Pharmaceuticals: quick answers

What stage is ANI Pharmaceuticals in?

As of Oct 22, 2026, ANI Pharmaceuticals (ANIP) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 27, 2026 and is in week 8. What the four stages mean

Is ANI Pharmaceuticals in an uptrend?

No. ANI Pharmaceuticals is in a Stage 4 downtrend. It trades 5.4% below its 200-day average, which is falling.

How far is ANI Pharmaceuticals from its 52-week high?

ANI Pharmaceuticals closed at $73.75 on Oct 22, 2026, 22.3% below its 52-week high of $94.90. Its 52-week low is $70.16.

How has ANI Pharmaceuticals performed over the past year?

As of Oct 22, 2026, ANI Pharmaceuticals is down 22.7% over the past year and down 6.0% so far in 2026.

Which sector and industry is ANI Pharmaceuticals in?

ANI Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry, part of the Health Care sector.

About this companyHealth Care· Drug Manufacturers - Specialty & Generic

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.